Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1983 1
1987 4
1988 1
1989 4
1991 1
1992 3
1993 2
1995 2
1996 2
1997 3
1998 1
1999 3
2000 7
2001 14
2002 22
2003 34
2004 25
2005 21
2006 19
2007 18
2008 16
2009 22
2010 29
2011 36
2012 37
2013 31
2014 35
2015 46
2016 38
2017 41
2018 35
2019 28
2020 33
2021 21
2022 15
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 12228201

555 results

Results by year

Filters applied: . Clear all
Page 1
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Herbst RS, et al. J Clin Oncol. 2002 Sep 15;20(18):3815-25. doi: 10.1200/JCO.2002.03.038. J Clin Oncol. 2002. PMID: 12228201 Clinical Trial.
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Baselga J, et al. J Clin Oncol. 2002 Nov 1;20(21):4292-302. doi: 10.1200/JCO.2002.03.100. J Clin Oncol. 2002. PMID: 12409327 Clinical Trial.
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. Ranson M, et al. J Clin Oncol. 2002 May 1;20(9):2240-50. doi: 10.1200/JCO.2002.10.112. J Clin Oncol. 2002. PMID: 11980995 Clinical Trial.
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. Ahn MJ, et al. Lancet Respir Med. 2017 Nov;5(11):891-902. doi: 10.1016/S2213-2600(17)30378-8. Epub 2017 Oct 19. Lancet Respir Med. 2017. PMID: 29056570 Clinical Trial.
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M. Nakagawa K, et al. Ann Oncol. 2003 Jun;14(6):922-30. doi: 10.1093/annonc/mdg250. Ann Oncol. 2003. PMID: 12796031 Free article. Clinical Trial.
555 results